申请人:The Green Cross Corporation
公开号:US05530001A1
公开(公告)日:1996-06-25
A novel pharmaceutical use of a dihydropyridine derivative of the formula (I) ##STR1## wherein R.sub.1, R.sub.2 and R.sub.3 are the same or different and each is an alkyl or the like; R.sub.4 is a hydrogen atom or the like; R.sub.5 is nitro, a halogenated alkyl, cyano or the like; X is a vinylene or an azomethine; A is an alkylene; and B is --N(R.sub.6) (R.sub.7) or a group of the formula ##STR2## wherein R.sub.6 and R.sub.7 are the same or different and each is an alkyl, an aralkyl, an aryl or the like; R.sub.8 and Ar are aryl or the like; and n is 0, 1 or 2, or an acid addition salt thereof for promoting PGI.sub.2 production, and for the treatment and prevention of hyperlipemia, arteriosclerosis and cerebral diseases.
一种新的药用途,使用公式(I)的二氢吡啶衍生物,其中R.sub.1,R.sub.2和R.sub.3相同或不同,每个是烷基或类似物;R.sub.4是氢原子或类似物;R.sub.5是硝基,卤代烷基,氰基或类似物;X是乙烯基或偶氮甲基;A是烷基;B是-N(R.sub.6) (R.sub.7)或公式的一个基团##STR2##其中R.sub.6和R.sub.7相同或不同,每个是烷基,芳基烷基,芳基或类似物;R.sub.8和Ar是芳基或类似物;n为0、1或2,或其酸盐,用于促进PGI.sub.2的产生,并用于治疗和预防高脂血症、动脉硬化和脑部疾病。